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Background: Burden of disease (BoD) studies have been conducted in numerous international settings since the
early 1990’s. Two national BoD studies have been undertaken in Australia, in 1998 and 2003, although neither study
estimated the BoD specifically for Indigenous Australians. In 2005 the Australian Government Department of Health
and Ageing Office for Aboriginal and Torres Strait Islander Health formally commissioned the University of
Queensland to undertake, in parallel with the second national BoD study, the “Burden of Disease and Injury in
Aboriginal and Torres Strait Islander Peoples” study, drawing on available data up to 2003. This paper aims to
explore the policy context and narrative in the lead up to commissioning the Indigenous BoD (IBoD) study,
focusing on relevant contextual factors and insights regarding the perspectives of key stakeholders and their
anticipated value of the study. It is part of a broader project that examines the uptake of evidence to policy, using
the IBoD study as a case study.
Methods: A systematic review of the literature was undertaken in late 2013 and early 2014, and the findings
triangulated with 38 key informant interviews with Indigenous and non-Indigenous academics, researchers, statisticians,
policy advisors, and policymakers, conducted between 2011 and 2013.
Findings: Contextual features which led to commissioning the IBoD study included widespread recognition of
longstanding Indigenous disadvantage, lower life expectancy than non-Indigenous Australians, and the lack of
an adequate evidence base upon which to determine priorities for interventions. Several anticipated benefits
and expectations of key stakeholders were identified. Most informants held at least one of the following expectations
of the study: that it would inform the evidence base, contribute to priority setting, and/or inform policy. There
were differing or entirely contrasting views to this however, with some sharing concerns about the study being
undertaken at all.
Conclusions: The IBoD study, in concept, offered the potential to generate much desired ‘answers’, in the form
of a quantified ranking of health risks and disease burden, and it was hoped by many that the results of the
study would feed into determining priorities and informing Indigenous health policy.
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This paper describes and analyses the commissioning of
the Australian Indigenous Burden of Disease (IBoD)
study published in 2007. We examine the lead-up to its
commissioning and the expectations of the range of
stakeholders involved. Before presenting this case study,
we offer a brief overview of the Global Burden of Dis-
ease (GBD) project.
The first GBD study, initiated in 1992 at the request of
the World Bank [1,2], was a major milestone in global
health and development, and an integral component of
the 1993 World Development Report [3]. The GBD and
its derivatives have undoubtedly influenced conceptual-
isation of the global health agenda, the determination of
health and related research priorities, and the allocation
of resources [4,2,5]. The underpinning concepts, metrics,
and their implications have continued to be critiqued,
debated, and further developed. The most recent GBD
study was published in 2015, drawing on 2013 data [6].
Burden of Disease (BoD) seeks to quantify the loss of
healthy life from disease and ill-health, and is conven-
tionally measured in disability-adjusted life years (DALY)
[3] and derivatives of these measures. The DALY is a
time-based measure that combines years of life lost due
to premature mortality and years lived with a disability,
metrics specifically developed to assess the BoD [7]. The
DALY was first developed in 1992 and has since been
widely applied to measure the BoD in populations [8].
The total loss of DALYs globally is referred to as the
GBD [3], and findings are typically presented in a variety
of ways including by region, country, and risk factor.
The GBD methodology and assessment of DALYs did
not go unchallenged, when first developed, with critics
identifying a number of problems, both conceptually and
empirically. While some of these concerns have been ad-
dressed in subsequent versions of the GBD and its meas-
urement and presentation, others remain. Early criticism
of the GBD and BoD approaches suggested the concep-
tual and technical basis for DALYs was flawed, its as-
sumptions and value judgements open to question [9],
and that the proponents of DALYs did not distinguish
between measuring the BoD and allocating resources
[10]. Others argued that not all disease burden could be
estimated, and that the investment needed for BoD stud-
ies would divert resources from other work and focus at-
tention on major diseases, with limited linkage to
interventions [1,11]. Reidpath et al. [12] suggested that
the lack of consideration of realistic contexts would re-
sult in a measure that underestimates the burden associ-
ated with morbidity in disadvantaged populations and
overestimates the burden in advantaged populations.
More recent critiques highlight the continued uncertain-
ties around health data and the future ideal to properly
count and account “for all the world’s citizens, so thatcomplex estimation techniques are not needed” [5]. How
data from under-serviced communities are accurately
reflected remains an issue of concern.
Following a major revision of the GBD, a comprehen-
sive re-estimation of disability weights was provided for
the full set of around 230 unique sequelae associated
with the array of disease and injury causes in the study
[4]. The GBD Study 2010, released in late 2012, provided
regional estimates of deaths and DALYs (using a new
method for calculation of DALYs). It was at that stage
the most comprehensive GBD study, producing com-
parative metrics for 291 different causes of premature
death and disability across 187 countries for the years
1990, 2005, and 2010 [13]. Due to improved definitions,
methods, and data, the results supersede all previously
published GBD results. The Australian BoD studies –
national, state and Indigenous – precede these modifications.
National BoD studies have been conducted in a range
of countries. Murray et al. [14], in their analysis of the
GBD Study 2010, cite 59 papers written on BoD studies
conducted in Australia, South America, the United
States, Europe, Asia, and Africa. Such studies reveal a
degree of applicability to national health policy and plan-
ning activities [15-17]. However, it is notable that, whilst
BoD studies have been conducted on a global and na-
tional level for the past two decades, fewer sub-national
studies have been undertaken and the IBoD study ap-
pears to be the first BoD study conducted with a specific
focus on an Indigenous or minority population.
Australian burden of disease studies
A national BoD and Injury study was first conducted in
Australia in June 1998, using the GBD methods adapted
to the Australian context and drawing on Australian
sources of population health data from 1996 [18,19]. A
Victorian state-based BoD study was also undertaken in
1998, to provide a comprehensive assessment of prema-
ture mortality, morbidity, and disability attributable to dis-
eases, injuries, and various risk factors in 1996, with
projections to 2016 [20]. This study was then updated for
the year 2001, to provide a second comprehensive assess-
ment of the health status of the Victorian population [21].
The BoD framework was not specifically applied to the
Australian Indigenous population in the national study,
nor was it a focus of subsequent state-based studies [22].
These earlier studies did not quantify the BoD for Indi-
genous Australians due to concerns about incomplete
Indigenous identification data in population datasets
[22]. It was a pilot BoD study in the Northern Territory,
published in 2004, that first focussed on both Indigenous
and non-Indigenous people [23]. This study used data
from 1994 to 1998 and argued that it was able to largely
overcome data constraints – it could access Indigenous
identification in both death certification and most
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parative data to identify health priorities and facilitate
more effective and efficient resource allocation, although
the study remained ‘exploratory’ due to concerns about
potential inaccuracies in the available data, with the
quality of data sources ranging “from ‘excellent’ in dis-
ease surveillance systems to ‘reasonable’ for the extrapo-
lation method of national averages” [23].
A second national Australian BoD study commenced
in 2003 to update and expand on the first [17]. It was
during this time that the Australian Government De-
partment of Health and Ageing (DOHA) Office for Abo-
riginal and Torres Strait Islander Health (OATSIH)
began negotiations with the University of Queensland
(UQ) to undertake, in parallel to the second national
study, an estimate of the BoD in Indigenous Australians,
also drawing on available data up to 2003 [22]. This was
formally commissioned in 2005, and took advantage of
the well-established and internationally recognised team
working at the UQ at the time. While the Indigenous
component was investigated at the same time as the na-
tional BoD study, findings and analyses were published
separately in a companion report as the ‘Burden of Dis-
ease and Injury in Aboriginal and Torres Strait Islander
Peoples 2003’ (hereafter referred to as the ‘Indigenous
Burden of Disease (IBoD) study’). The work was finalised
in 2007 and published in a 2007 report [22] and a peer-
reviewed paper in 2009 [8].
Methods
The present paper reports on one component of a larger
NHMRC-funded study on evidence and policy in Abori-
ginal health, using the IBoD study as a case study for
analysis. The objectives of the broader study were to i)
explore how meaning is constructed from the IBoD re-
search evidence by different policy stakeholders; ii) con-
sider prioritization through BoD with other approaches
in priority setting; iii) map out the implications for the
use of different data, frameworks, and approaches for
priority determination and agenda setting; iv) identify
ways to enhance the use of research evidence in policy;
and v) extend the current theoretical base of health pol-
icy analysis.
This particular paper draws on data collected from a
literature review, a systematic review, and key informant
interviews, to elucidate the story behind the IBoD study
– why it was commissioned, the context in which this
occurred, and the expectations of the different stake-
holders involved. It complements our study on the
measurement and presentation of the life expectancy
gap in Indigenous health [24] and will sit alongside re-
lated papers examining the process and findings of the
IBoD study.A background literature search for relevant ‘grey litera-
ture’ was undertaken in 2013. Key materials from the
IBoD study itself were also accessed, including, for ex-
ample, the Agreement between DOHA and UQ, and
agendas and minutes from Steering Committee (SC) and
Technical Advisory Panel (TAP) meetings. In our Dis-
cussion, we refer to literature and frameworks from
Bowen and Zwi [25], Head [26,27], Walt [28], Nutbeam
and Boxall [29], and Kingdon [30] to reflect on the role
of research and evidence in the policy process.
The systematic review undertaken in November 2013
utilised Scopus, Informit e-library, and ProQuest Central
to identify all literature that referenced the IBoD study
in Australia, to assess how and in what ways data has
been used and/or taken up in policy and/or practice.
The search strategy utilised a combination of the follow-
ing search terms: ‘Burden of disease and injury in Abori-
ginal and Torres Strait Islander Peoples’; [OR] ‘Burden
of disease’ AND ‘Aborigin*’. No inception date was
chosen to ensure all relevant publications were captured;
all materials up until the search on 5 November 2013
were included. Grey literature was also included from
searches within key institutions and organisationsa from
2007 to date. Findings from this systematic review are
being written up in a separate paper; here, we draw on a
small number of the relevant papers identified.
A total of 38 key informant interviews were conducted
between 2011 and 2013 with Indigenous and non-
Indigenous academics, researchers, statisticians, policy
advisors, and policymakers. The interviews focussed pri-
marily on the background to commissioning the IBoD
study and expectations regarding its relationship to pol-
icy and practice. The subjects for interview were identi-
fied using ‘events-based sampling’ [31]; the ‘event’ being
the commissioning and implementation of the IBoD
study, and the critique on its release. The sample com-
prised members of the IBoD research team, SC and TAP
members, overt critics of the research, and those respon-
sible for applying its findings into policy. All identifiable
stakeholders directly involved in the process were con-
sidered relevant informants, and were contacted by
email or telephone and invited to participate. The re-
sponse rate was high, with only two declining and one
stakeholder deceased.
Interviews were semi-structured, using question lines
developed by team members, and were conducted face
to face, and in a small number of cases, by telephone.
Consent for the interview was noted on paper or at the
commencement of the interview, which was recorded
and subsequently transcribed. Informants were divided
into five groups for the analysis (academic, member of
IBoD research team, statistician, policy advisor, or pol-
icymaker), and NVivo 10 [32] was used for organising
and coding the data. Coding involved independent
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the research team, who developed a coding frame based
on the major themes emerging. Coding of all interviews
was undertaken by one person in NVivo 10 [32], who
identified additional codes as needed. Upon completion
of this, the coding was independently checked by an-
other person, and consensus on final themes and associ-
ated codes was agreed.
Ethics approval was obtained from the Behavioural
and Social Sciences Ethical Review Committee at the
UQ (approval number 2010001442).
This paper is structured around answering the follow-
ing questions:
i. What were the main contextual factors that led to
the commissioning of the IBoD study?
ii. How was the IBoD study commissioned, and who
was involved in this process?
iii. What were the expectations of stakeholders in
relation to the IBoD study, in the lead up to and
during the commissioning?
iv. How does this case study relate to the literature on
the use of evidence in the policy process?
This paper critically examines the background and
policy context, preliminary negotiations, and the narra-
tive culminating in the commissioning of the IBoD
study. We consider the motivation behind the study and
the anticipated value of the study by key stakeholders.
The paper focuses primarily on three key areas: the con-
textual factors in the lead up to the commissioning of
the IBoD study, the commissioning process itself, and
the expectations of stakeholders.
Findings
Contextual factors leading to the commissioning of the
Indigenous Burden of Disease (IBoD) study
Indigenous health in the 1990’s and early 2000’s
The context in which the IBoD study was commissioned
was characterised by widespread recognition of Indigen-
ous disadvantage and inequities in health and its determi-
nants. High levels of inequalities in mortality, morbidity,
life expectancy, and a raft of other health indices had been
well documented [33-35]. The infant mortality rate for the
Indigenous population was almost three times that of the
general Australian population [35,36]. While precise life
expectancy rates and the gap between Indigenous and
non-Indigenous Australians are contested [24,37], in 2005
the gap was estimated to be “about 17 years” [38]. The
Australian Bureau of Statistics (ABS) released their inaug-
ural biennial report ‘The Health and Welfare of Australia’s
Indigenous Peoples 2003’ in 2003, which argued that Indi-
genous Australians had a life expectancy that “is about 20
years shorter” than non-Indigenous Australians, andsuggested that Indigenous people suffer disproportionately
from the consequences of European settlement, with
many living in conditions of economic disadvantage due
largely to lower education and employment levels [36]. As
commented by McMurray [37], the 17-year difference in
life expectancy, based on the 1996–2001 estimates, be-
came well known and was important in the development
of Indigenous policy by Australian governments.
National concern regarding the inequitable state of In-
digenous health in the early 2000’s was apparent, with
both government and the public health community con-
cerned. One academic interviewed noted that: “Australia
was a kind of international pariah, for its failure to
tackle Aboriginal health. We had gone through decades
of the era of what I call unfunded policy. Aboriginal
Health is bad” and “Aboriginal health in this country
has been, arguably, the biggest public health failure in
the western world”. Political pressure was clearly mount-
ing, with numerous organisations and individuals seek-
ing improvements in Indigenous health: “[Australia]
would pontificate all around the world about human
rights, and other people would say… if you were really
serious about human rights you would sort out the mess
in your own backyard” (Academic). A policy advisor
stated that: “…for a long time [there has] been a strong
will on the part of governments of either political persua-
sion to improve Aboriginal and Torres Strait Islander
health, and a desire on the part of the Australian De-
partment of Health and Ageing to be improving Aborigi-
nal health”.
Table 1 provides additional context and highlights this
ongoing interest and concern around Indigenous health
through a chronology of key policies, reports, and events
from 1998 to 2013.
Lead-up to the commissioning of the study
Routine data collection systems often underestimated
the true rates of ill health in Indigenous populations due
to poor quality data, including inadequate Indigenous
identification in health service utilisation records [22].
One policy advisor suggested that: “the problem in Indi-
genous health was a lack of good knowledge of Indigenous
health” and another advisor that: “… there was a recogni-
tion that our traditional measures were really not up to
it. They just weren’t satisfactory”. A policy advisor in the
Northern Territory argued that: “the issue of Indigenous
identification has been a priority for the last 15 to 18
years, and some states really still can’t report”. There
had also been considerable uncertainty about the precise
level of mortality, as well as disease incidence and preva-
lence, among Indigenous Australians. The need for good
quality and accessible data on Indigenous peoples was
evident – for benchmarking, to assess the effectiveness
of programs and interventions, and to evaluate policies [36].
Table 1 Chronology of relevant policies, reports, and events (1998–2013)
Year Australian
BoD studies








2000 Final report of the Council for Aboriginal Reconciliation
to the Prime Minister and the Commonwealth Parliament
delivered (December)
2001 National Health Performance Framework released
(September)
Federal election (November)
2002 COAG agreed to commission the SCRCSSP to
produce a regular report to COAG against key
indicators of Indigenous disadvantage, to






Inaugural biennial report The health and welfare of
Australia's Indigenous Peoples 2003 published (ABS &
AIHW)
Overcoming Indigenous disadvantage: key indicators







Governmental changes regarding a ‘whole-of-
government’ approach to Indigenous affairs at
Federal level implemented (July)
The 2002 National Aboriginal and Torres Strait




Health and welfare of Australia's Aboriginal and Torres
Strait Islander peoples, 2005 published (ABS & AIHW,
August)














Oxfam Close the gap: solutions to the Indigenous health
crisis facing Australia report released (April)
Northern Territory Intervention
(June 07–October 08)
Australian DOHA: National Strategic Framework
for Aboriginal and Torres Strait Islander Health
2003–2013: Australian Government
Implementation Plan 2007–2013
2008 National Indigenous Reform Agreement (November) National Apology (February)
Indigenous Chronic Disease Package (November) Close the Gap: Indigenous Health Equality
Summit – Statement of Intent (March)
Closing the Gap framework (December) National Partnership Agreement on Closing the










National Health Performance Framework revised New life expectancy estimates released
(ABS, May)
2010 Closing the Gap: The Indigenous Chronic Disease
Package in 2009–10 (first annual report)
2011 2010 Indigenous Expenditure Report (first edition)
(February)
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Table 1 Chronology of relevant policies, reports, and events (1998–2013) (Continued)
Closing the Gap: The Indigenous Chronic Disease
Package in 2010–11 (second annual report) (October)
2012 Aboriginal and Torres Strait Islander Health
Performance Framework
2012 Indigenous Expenditure Report (second edition)
(September)
2013 The Aboriginal and Torres Strait Islander Peoples
Recognition Bill 2012 passed (February)
Federal election (September); Liberal Coalition
government elected under Prime Minister Tony
Abbott
Closing the Gap: Prime Minister’s Report 2013 released
Australian Aboriginal and Torres Strait Islander Health
Survey: First Results, Australia, 2012–13 released
(November)
ABS, Australian Bureau of Statistics; AIHW, Australian Institute of Health and Welfare; BoD, Burden of disease; COAG, Council of Australian Governments; IBoD,
Indigenous burden of disease; SCRCSSP, Steering Committee for the Review of Commonwealth/State Service Provision.
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DOHA were keen to improve the evidence base, and an
IBoD study provided an opportunity to do so and ex-
pand on knowledge of Indigenous health. The IBoD re-
searchers argued that the “Burden of disease estimates
for Indigenous Australians…would help to identify those
diseases and risk factors that are most responsible for the
gap in health status between Indigenous Australians and
the Australian population overall” and that these data
would add value: “OATSIH recognised the value of fund-
ing a study that would improve the evidence base for de-
termining the size and impact of health problems in the
Indigenous population, using a ‘burden of disease’ method-
ology” [22]. An Indigenous academic interviewed sug-
gested that: “from OATSIH’s point of view I think that
they genuinely were interested in getting a better handle
on the burden of illness in Aboriginal communities”, and
a policymaker that: “[OATSIH] had made a very long
term commitment… that we would work in a concerted
way to try and improve the data holdings… Having that
[IBoD] work done within Australia was part of our inter-
national obligations, but also would significantly improve
what we were doing around health status…”.
In 2003, it was considered opportune to garner in-
sights into the state of Indigenous health by applying
BoD metrics; this also took advantage of the presence of
leading members of the GBD team being based at the
UQ. According to one policy advisor “…it was the logical
step. Alan Lopezb does the global Burden of Disease
study. He comes to Australia and does the Australian
Burden of Disease study, and we were all sitting around,
and we needed an Indigenous Burden of Disease study”.
In addition, as noted previously, several national and
state-based BoD studies had previously been conducted
in Australia, with the first national report being: “…very,
very popular and… used hugely in policy, in ministerial
briefings all over the place” (Government statistician).
The importance of these earlier experiences inpromoting an IBoD study was also highlighted by other
informants: “Treasury were familiar already with the
Burden of Disease concept and were quite taken with it”
(Policymaker) said one, while another commented that
the earlier BoD study for the Victorian government was
very well received: “I think that was certainly looked at
and…that was very, very well communicated I thought by
the Victorian government and I think that was a key fac-
tor in selling the Burden of Disease work to the Common-
wealth” (Policy advisor).
Commissioning of the IBoD study
Key stakeholders
Many individuals and organisations were involved in the
commissioning and implementation of the IBoD study.
OATSIH commissioned and funded the UQ to under-
take the study, under the leadership of Professor Alan
Lopez and Dr Theo Vos. The SC was formed in 2005
and comprised representatives from the National Aborigi-
nal Community Controlled Health Organisation (NAC-
CHO), OATSIH, the Australian Institute of Health and
Welfare (AIHW), the ABS, UQ, University of Melbourne,
University of Wollongong, Edith Cowan University, James
Cook University, and the Northern Territory Department
of Health and Community Services. A TAP was also
formed in 2005, with a smaller team of members from
the ABS, AIHW, Menzies School of Health Research,
Queensland Department of Communities Office of
Aboriginal and Torres Strait Islander Partnerships, and
the Northern Territory Department of Health and
Community Services. The SC and TAP are discussed in
further detail later in this paper.
Existing relationships and networks leading to the
commissioning
Indigenous and non-Indigenous academics and policy-
makers identified informal networks between the policy
and research community as “pretty powerful”, “pretty
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critical”. Many of those interviewed noted that existing
relationships, networks and advocacy all played a role in
the commissioning of the IBoD study. One policymaker
reinforced this: “… who you know, who phones you up,
who you meet at a conference, who gets your attention…
it certainly helps”.
One example of this is that Dr Vos, one of the
lead authors of the IBoD study, had been involved in
both the national and Victorian BoD study. Treasury
were therefore familiar with him and the BoD con-
cept, as noted by several informants. One policy-
maker suggested that it was “probably a mixture of
strong advocacy by the researchers and a view on the
part of the [DOHA employee] that it would yield
something useful… I think there was quite a sort of
close relationship between the researchers and the
[DOHA employee]. So there was probably a little bit
of a sort of amicable agreement that this would be
something worth doing”. Professor Lopez, who pro-
vided oversight of the IBoD study and was Chair of
the SC, was also known to senior employees of the
DOHA, who were keen to undertake the second
BoD national study in Australia.Commissioning process
Commissioning the IBoD study in 2005 seems to have
been a relatively simple addition to the national BoD ac-
tivities already underway, and there was broad agree-
ment by a range of informants that the Indigenous study
was seen as a component of the national study – “we
didn’t even consider it a separate project; we considered
it an element of what the overall study was going to do”
(Research team member); “it really was a subset. We
couldn’t have done the Indigenous study without first…
doing the Australian one” (Research team member); “So
once all the methodology for the first Australian study
were updated into the second national study, then that
provided the opportunity to do [the] Indigenous Burden
of Disease study as a supplement to the second national
study” (Policy advisor); and “The Indigenous study was
funded by OATSIH and it was produced separately but
within the envelope of the national Burden of Disease
study” (Government statistician).
One member of the IBoD research team confirmed
that OATSIH contributed funds for the Indigenous com-
ponent of the national BoD funding package, and noted
that the research team agreed that whilst they could do
the Indigenous component “with difficulty”, they “would
certainly see that as a priority part”. This informant sug-
gested the IBoD study “wasn’t a purposeful ‘we will do a
study of sub-populations’… But it was just that part of
[the] funding package and interest came from OATSIH”.A series of five contracts were put together by DOHA,
each for different components of research (including the
national BoD study and the IBoD study), with different
groups within DOHA having an interest in specific as-
pects of the research. This complex arrangement led to
an Indigenous academic informant suggesting that the
“Government’s process of commissioning… [the IBoD
study] was really poor” and another informant that “…
the contracts were appallingly written”. The incremental
addition of the IBoD study may have contributed to the
concerns of one government statistician that there was
also inadequate consultation with the National Advisory
Group on Aboriginal and Torres Strait Islander Health
Information and Data: “…there is no evidence here to me
that that was done… I’m not surprised. Disappointed,
but I’m not surprised” (Government statistician).Process to engage stakeholders and their planned
involvement in the study
As previously mentioned, two groups were established
to support the IBoD study: a SC to provide guidance
and ensure the study provided relevant information for
policymaking and advocacy, and a TAP to discuss meth-
odological issues [22]. According to the contract be-
tween DOHA and the UQ, the “Burden of Disease
Steering Committee, appointed by the Participant (UQ),
will be chaired by Professor Alan Lopez and consist of ex-
perts and representatives of national Indigenous commu-
nity organisations as well as a representative from
OATSIH, to be appointed by the Department. The SC
will guide the study to ensure the study provides relevant
information for policymaking and advocacy. The SC will
also provide scientific guidance and scrutiny of the study
team’s interpretation of the evidence. A technical sub-
committee will be formed to discuss methodological is-
sues” (Unpublished data). This contract also stated that
the UQ and AIHW must ensure that the study received
guidance and intellectual input from Professor Lopez
and Dr Vos, and must consult with OATSIH, both of
which it did.
According to the contract, the UQ were also to con-
sult with epidemiological experts and Indigenous com-
munity organisations at both national and state/local
level. While epidemiological consultation did occur
through the TAP and BoD networks, there is limited
evidence of any formal engagement with Indigenous
organisations, except perhaps through several SC
members. The new Cooperative Research Centre for
Aboriginal Health, in which the UQ was a partner,
was to also provide expertise and foster collaboration
with Indigenous community organisations (Unpub-
lished data), which does not appear to have happened.
A representative of NACCHO was nominated to the
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policy, were also appointed.
Whilst consultation with Indigenous community orga-
nisations was written into the contract, there appears to
have been relatively little Indigenous engagement during
the commissioning process. Several informants subse-
quently aired concerns with this. An Indigenous aca-
demic stated “I don’t know that the Indigenous issues
were really front and centre in it” and “I think the fact
that it was commissioned like it was… it was really, you
know, the horse has bolted, and now we’ve got to find a
way of getting some form of Indigenous engagement and
endorsement in the process”. This informant also sug-
gested there was a “lack of Indigenous leadership at the
time of the project…”.
Several informants also critiqued the IBoD research
team for having inadequate insights into the specificities
of Indigenous health research. A policy advisor inter-
viewed suggested that the researchers “… didn’t have a
good understanding of the Indigenous research and polit-
ical environment… [there was] a lack of political know-
ledge and links into the Indigenous research environment…
And that engagement was then problematical, because
they were seen as outsiders coming into a patch where
people had 15, 20 years or more experience in research”.
An Indigenous academic also noted that “the friability
and the weakness of this network was there weren’t
enough Indigenous players who were connecting to those
other policy networks and saying, ‘Hang on, this is a bit of
work that’s got some methodological problems, it’s got
some data problems, but it is pointing to some very im-
portant stuff that we need to bring into the mix.’ And
that’s the other thing you lose, if you don’t have good
Aboriginal participation in the process. You lose all that
network of connection”.
According to the minutes of the first SC meeting in
2005, there was “not an Indigenous person represented
on the TAP. There was general agreement from the steer-
ing committee members that an Indigenous person
should be invited to sit on the TAP so as to assist with
the interpretation of technical issues. [An SC member]
commented that an effort had been made to include an
Indigenous person with epidemiological expertise on the
TAP … but this had not been achieved due to the per-
son’s time commitments” [39]. One Indigenous academic
was active in the TAP, but with policy, rather than epi-
demiological expertise. Whilst a key peak Indigenous
body had been invited to sit on the TAP, they were not
available to do so.
Opposition to the study
Several informants from at least one government agency
indicated that concerns with the availability and quality
of Indigenous data led them to be less involved in, orsupportive of, the IBoD study. Many were uncertain
whether existing data would support an IBoD study,
given the poor quality of data, under-reporting (particu-
larly in certain jurisdictions), and the inconsistent identifi-
cation in other data sources. One government statistician
stated “I didn’t think that the data would support it” and
that “the problem with Indigenous data is that it is beset
by problems which really stem from changing rates of iden-
tification over time and it’s very hard to understand those
things and to allow for the issues which vary from place to
place and from time to time and from topic to topic”.
Minutes from the first meeting of the SC show one
member suggested they were initially “…sceptical of its
applicability due to the wide-ranging and well-known
deficiencies in Indigenous data” [32]. Concerns were
also expressed that the findings of the IBoD study may
be unpredictable and disrupt accepted positions, with
one academic apprehensive that “this [IBoD] project, rather
than helping, might screw… up [the current government
estimates of the 17 year life expectancy gap]. That was
our worry”.
According to a policymaker interviewed, even while
the commissioning process was underway, there contin-
ued to be some debate within OATSIH as to whether
they should support the study or not: “we, relatively
early on, were involved in a process about whether or
not we were going to invest in the Vos work, and there
was quite a long debate about methodology… we’d
already made a commitment by then, there was some
pressure by some participants as to whether we should
continue to support it, and we made a decision that we
would”.
Expectations of stakeholders in the lead up to,
and commissioning of, the study
Key informant interviews identified three broad but
inter-related expectations of the IBoD study, with many
stakeholders sharing at least one or more of these. These
are closely related and included improving the evidence
base, informing policy discussions, and contributing to
priority setting.
A recurring theme across many interviews was around
both the perceived lack of reliable data for Indigenous
health, and the hope that the IBoD study would generate
metrics to allow better interpretation and use of existing
data. Informants noted that while improvement was
needed, it was not only the generation of new metrics
and analyses that was deemed important, but also en-
hancing its quality and reliability. A policy advisor and
policymaker expressed these viewpoints: “… it was a
very clear recognition that we needed to improve our epi-
demiological analysis of the data we had, and what
could be brought to bear on the range of data that was
available”; “…we’d made a very long-term commitment…
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prove the data holdings”. An Indigenous academic also
suggested that: “from OATSIH’s point of view I think that
they genuinely were interested in getting a better handle
on the burden of illness in Aboriginal communities”, and
a policy advisor that: “the Department are very wedded
to improving the evidence base”. Other informants artic-
ulated similar viewpoints, stating: “we knew that … the
better the evidence base, the better armed we will be”
(Policy advisor). It was argued by a policymaker that
OATSIH had “made a very long term commitment
through some Commonwealth [and] state committees
and through relationships that we had… that we would
work in a concerted way to try and improve the data
holdings … it was also quite a strong commitment
around evidence-based policy and about being able to
measure whether what you’re doing makes sense. And so
always being able to search for how you can draw on
data that’s real and meaningful and measurable was a
real drive for us”.
One policy advisor noted the value of quantification,
both in relation to commissioning the work: “So govern-
ments of all persuasions will invest in finding more about
a problem through research into issues that have a par-
ticular quantitative bent”, and in building on the par-
ticular strengths of the BoD methods: “So I guess we
were trying to quantify those things, which the method-
ology is particularly good at, and other forms of health
data don’t – Indigenous health data don’t give us…”. Nu-
merical data were seen as being particularly powerful
and potentially influential within the policy environment,
by both a policymaker and an academic interviewed: “…
so always being able to search for how you can draw on
data that’s real and meaningful and measurable was a
real drive for us” and “I think the burden of illness… may
be useful to all in advocacy in trying to raise awareness
or something”.
The value of quantifying and synthesizing a range of
disparate data in order to shed light on differences and
key areas of focus was also intimated by a member of
the IBoD research team: “Putting it all together, in a
consistent framework where you can quantify it in the
same way against each other and be able to say, these
are the big health problems, at these ages, men versus
women, remote versus non-remote, this disease versus
that risk factor, now, that’s a huge step forward”. An-
other informant emphasised the value of data that
directly compared Indigenous and non-Indigenous ex-
perience, thus contributing to focusing on where
change was needed: “I think one of the valuable things
that we were hoping to get out of it was just the Indigen-
ous/rest of Australia comparison. So you could actually
have some evidence as to where to focus to make a dif-
ference” (policy advisor).Informants identified the inherent attractions to a
metric that helps generate a single number upon which
estimates can be based and which can set priorities and
inform policy. The value of numerical data was
highlighted by one academic: “You’ve got policymakers
saying, ‘We’re not interested in your technical ifs and
buts, give us the number’”, implying that one could work
with numbers but not uncertainty which often accompan-
ies them. This reinforces a well-observed policy concern
with quantification, as described in other Australian stud-
ies focused on other policy issues [40]. Another academic
interviewed also noted concern about quantification, stat-
ing: “I’m not opposed to quantification. Quantification can
bring rigour. What I’m opposed to is quantifying for the
sake of quantification or quantifying something over here
because we can’t quantify (t)here”.
Several informants did express concern about the
quality of the data the IBoD study was to work with,
and whether it would produce reliable results, as pre-
viously noted. One government statistician suggested
“the problem with the Indigenous Burden of Disease was
really, the quality of the data was an issue. And it cre-
ated quite a bit of angst among the Steering Committee
in general” and that “the Indigenous issue is problematic
because of the quality of the Indigenous data”. Minutes
from the first SC meeting showed that, while one mem-
ber was initially sceptical of the applicability of the
study due to “the wide-ranging and well-known defi-
ciencies in Indigenous data” [39], they came to realise:
“…there was lots of value in going through the exercise
and putting up estimates as one of the outcomes of the
process would be identifying strengths and gaps in health
datasets which would aid future studies in Indigenous
health” [39].
Two additional anticipated benefits that emerged from
the interviews was the hope that the evidence from the
IBoD study would inform policy and contribute to prior-
ity setting, as the study was: “… policy relevant from the
outset” (Indigenous academic). The IBoD researchers
themselves were confident of the pertinence of the re-
search to policy and priority setting: “I guess I hoped that
it would be used as evidence in informing policies”, and
“People working on it, I think, were passionate about
these results [and that they] would influence policy, or
these results would make a difference… it would give an
overview, as I said, so then people could decide where to
target resources to make the biggest difference”. One se-
nior policymaker also confirmed early expectations of its
value: “[Treasury] saw it as, even then, potentially useful
for policy”.
An opposing view about the study’s potential contribu-
tion to policy was articulated, however, with one academic
suggesting the “…development of policy is multi-faceted.
The numerical data… they’re only a small part of the
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economic setting, and all the rest of it, that is really funda-
mentally determinative. Put it this way, we don’t lack ef-
fective policies for Indigenous health in Australia because
we lack data”. Nevertheless, alongside this strongly held
view, were repeated calls by other informants for more
and better data.
For some academics and the IBoD researchers, the ul-
timate value of the IBoD study lay in its capacity to inform
resource allocation: “It’s about establishing and confirming
priorities”; “it was a good and useful kind of thing in sort of
priority setting and this sort of stuff”; and “then people
could decide where to target resources to make the biggest
difference”. One policy advisor also suggested that the
study might improve understanding of more neglected
areas, such as mental health: “… that’s where the Depart-
ment, I’m sure, was seeking to draw on those areas where
we didn’t have a good understanding. And the Burden of
Disease methodology… [would] close the knowledge gap
around mental health issues and so forth”.
Not all informants held these views about resource al-
location though, with one critic commenting that the
IBoD study: “…as a methodology for priority setting… it’s
a waste of time and potentially misleading, because to
know the size of a problem tells you nothing about what
to do about it” and that “I think we knew [the priorities]
before” (Academic). Another academic similarly sug-
gested that the focus should not be on establishing pri-
orities to direct resources, but in identifying strategies
that were going to make effective use of the resources,
and that “energy needs to be directed to the search for
new and novel ways of addressing the problems”.
Discussion
Indigenous Australians suffer disproportionately to non-
Indigenous Australians, often living in conditions of so-
cial and economic disadvantage, and experiencing worse
health [38]. Despite acknowledgement of vast differen-
tials in health status, evidence has been limited to trad-
itional population health indicators. At the time the
IBoD study was commissioned, there was some uncer-
tainty around underestimation of levels of mortality and
disease in Indigenous Australians due, in part, to under-
enumeration of those of Indigenous identity and imprecise
routine data collection systems [22]. OATSIH funded the
IBoD study in an effort to improve the evidence base in
Indigenous health and contribute to priority setting and
resource allocation, and used the opportunity to source lo-
cally available global expertise in the GBD team.
There is widespread recognition of the value of policy
being informed by evidence [25,26,41], and “rigorous re-
search findings are seen as useful and necessary inputs
for policymakers in their ongoing consideration of policy
development” [26]. According to Head, three enablingfactors underpin evidence-based policy: “high-quality
information based on relevant topic areas, cohorts of
professionals with skills in data analysis and policy
evaluation, and political incentives for utilising evidence-
based analysis and advice in governmental decision-
making processes” [27]. All three of these enablers were
arguably present and help explain why the study was
commissioned.
The literature reminds us, however, that policymakers
are not automatically attracted to drawing on research
to inform their policy proposals: “Clearly politics may
affect how much notice policy makers take of research re-
sults. Where governments are committed to policy on
ideological grounds, they may be only secondarily inter-
ested in research findings, especially if these challenge or
question the policy impetus, its ideological basis or au-
thoritative knowledge” [28]. In the context of Indigenous
health in Australia, Nutbeam and Boxall [29] argued that
the Howard government (in power when the IBoD study
was commissioned) placed its focus “on addressing indi-
vidual risk factors for ill health”. This, too, would have
been in keeping with the BoD approach and assessment
of risk factors requiring intervention.
Research may be commissioned by governments to
underpin a particular policy objective or direction, per-
haps in support of an issue already on the policy agenda,
or to shed light on a question for which the answer is
unknown. It may also help to select between different
intervention options. The Australian government at the
time of the commissioning of the IBoD study was clearly
committed to improving Indigenous health data and im-
proving Indigenous health outcomes. Having research
commissioned by government also increased the likeli-
hood of utilisation of the products of that research by
policymakers. As one policy advisor interviewed stated:
“… in terms of one of your questions about stakeholders
and how to get policymakers involved, certainly as I was
saying before, where the Department is involved in the
development [it] is quite good. Like the development of
[the IBoD study] – a lot of communication helps in terms
of then implementing the findings”. The literature bears
this out, as stated by Davis and Howden-Chapman [42],
who highlight the indirect links between research and
policy, but state nevertheless that: “researchers can reframe
the way health policy issues are seen, and collaboration with
policymakers initially can enhance implementation later”.
Commissioning of the IBoD study was facilitated by
the experiences of previous national and state-based
BoD studies, as well as existing relationships between
the government and researchers involved. Haynes et al.
[43] note that existing relationships between policymakers
and researchers are key to researchers influencing policy
and “good interpersonal relationships between researchers
and policymakers are consistently identified as key
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(p. 1). An Australian study exploring the views and prac-
tices of policymakers and researchers with respect to the
use of evidence in policy also found that existing relation-
ships and networks with policymakers facilitated use of re-
search evidence [44]. Relationships such as these clearly
played a considerable role in the commissioning of the
IBoD study, as did existing networks which are often the
route through which policymakers engage researchers
[43,45].
Across the range of informants interviewed, many iter-
ated at least one of three related areas of anticipated
benefit: informing policy, improving the evidence base,
and priority setting. These findings demonstrate a num-
ber of shared interests amongst the range of stake-
holders in having the IBoD study undertaken.
These expectations identified highlight an approach to
policymaking that places emphasis on numbers and re-
search data. It suggests a ‘rational’ approach to policy-
making, seeing it as a somewhat technical activity in
which numbers and quantification play a key part. The
IBoD study, especially in concept, offered the potential
to generate much desired ‘answers’ in the form of num-
bers. It seems that hard numbers, and an assumed rela-
tively ‘objective’ method, were seen as helping advance
an area in which few significant gains had been made,
that was contentious politically, and for which new
thinking was required. It was clearly hoped that the re-
sults of the study would feed into determining priorities
and informing policy. The ranking of a range of condi-
tions was, and still remains, a prominent feature of BoD
studies globally and nationally, so if policy is seen as
reflecting the allocation of effort and resources to
achieve a particular outcome, the potential importance
of such data in influencing Treasury and the allocation
of funds to key areas of Indigenous health is apparent.
To some extent the commissioning of the IBoD study
could be seen as addressing Kingdon’s three streams:
problem, politics, and policy [30], coming together in
the hope that the study would offer answers and help
progress in the field. There was clear recognition of a
problem – inequalities in health status of Indigenous
Australians, a desire to find policy solutions that would
make a difference, and bipartisan political support for
addressing Indigenous disadvantage. The IBoD study of-
fered new metrics and the potential to identify key areas
for future investment and intervention.
Whilst many of those interviewed noted at least one of
the three key expectations identified, several inter-
viewees held slightly differing or completely opposing
views. This may be indicative of their personal experi-
ences with BoD studies, organisational base and role,
prior views on what needed to be done to improve Indi-
genous health in Australia, or their views of the value ofcommissioned research and quantitative data to policy
decision-making. Furthermore, as noted previously, cri-
tiques of the IBoD study by some informants were that
existing data would not support the study, that numbers
would not address the underlying issues of concern
(which were dominated by socio-political concerns and
social determinants of health), and that findings might
compete with other available estimates.
A key limitation during the commissioning process,
likely to influence the uptake and use of the IBoD study,
was the noted lack of Indigenous engagement with the
study. While some efforts were made to involve Indigen-
ous academics and organisations within the commission-
ing and oversight of the study, those that were involved
were there in a personal capacity and informal policy
role. The one official Aboriginal community-controlled
organisation invited to participate was unable to do so.
As noted previously, this is likely to have influenced how
the study may have been conceptualised and positioned
within the policy debates around Indigenous health
inequalities.
A comment on limitations within our study is also ap-
propriate to note. These insights were derived primarily
from a series of interviews undertaken several years after
the IBoD study was published, and may have therefore
been influenced by informant views on the study out-
comes, in this way differing from their views at the time.
While reflecting post-hoc analyses, rather than real-time,
these were supplemented by the literature of the time
and other relevant documentation. While many infor-
mants were willing to share potentially sensitive insights
and data, other ‘behind-the-scenes’ views may not have
been shared with us.
Conclusions
The Indigenous health context in the lead-up to the
commissioning of the IBoD study included concern
around longstanding Indigenous disadvantage, shown
through high mortality and morbidity differentials, lower
life expectancy than non-Indigenous Australians, and
the perceived lack of an adequate evidence base upon
which to determine priorities for interventions. It was
within this broad context that the IBoD study was
commissioned. We identified several anticipated benefits
and expectations of key stakeholders, including Indigen-
ous and non-Indigenous academics and bureaucrats
from a range of institutional bases. Many informants
noted that they hoped the study would inform the evi-
dence base, contribute to priority setting, and/or inform
policy. The IBoD study offered the potential to generate
much desired ‘answers’, in the form of numbers, and it
was anticipated by many that the results of the study
would feed into determining priorities and informing In-
digenous health policy. A notable lack, however, was the
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have influenced how the study outcomes were subse-
quently used. A recently commissioned second IBoD
study, led by the Australian government utilising 2013
data, may well approach this process differently.
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